173 related articles for article (PubMed ID: 20422244)
21. A subset of prostatic basal cell carcinomas harbor the MYB rearrangement of adenoid cystic carcinoma.
Bishop JA; Yonescu R; Epstein JI; Westra WH
Hum Pathol; 2015 Aug; 46(8):1204-8. PubMed ID: 26089205
[TBL] [Abstract][Full Text] [Related]
22. Adenoid Cystic Carcinoma/Basal Cell Carcinoma of the Prostate: Overview and Update on Rare Prostate Cancer Subtypes.
Cozzi S; Bardoscia L; Najafi M; Botti A; Blandino G; Augugliaro M; Manicone M; Iori F; Giaccherini L; Sardaro A; Iotti C; Ciammella P
Curr Oncol; 2022 Mar; 29(3):1866-1876. PubMed ID: 35323352
[TBL] [Abstract][Full Text] [Related]
23. Adenoid cystic carcinoma of the prostate: case report on a rare entity and review of the literature.
Ahuja A; Das P; Kumar N; Saini AK; Seth A; Ray R
Pathol Res Pract; 2011 Jun; 207(6):391-4. PubMed ID: 21440997
[TBL] [Abstract][Full Text] [Related]
24. Clinical Relevance of Incidental Prostatic Lesions on FDG-Positron Emission Tomography/Computerized Tomography-Should Patients Receive Further Evaluation?
Reesink DJ; Fransen van de Putte EE; Vegt E; De Jong J; van Werkhoven E; Mertens LS; Bex A; van der Poel HG; van Rhijn BW; Horenblas S; Meijer RP
J Urol; 2016 Apr; 195(4 Pt 1):907-12. PubMed ID: 26598424
[TBL] [Abstract][Full Text] [Related]
25. Basal cell carcinoma of the prostate: a clinicopathologic study of 29 cases.
Ali TZ; Epstein JI
Am J Surg Pathol; 2007 May; 31(5):697-705. PubMed ID: 17460452
[TBL] [Abstract][Full Text] [Related]
26. Squamous cell carcinoma of the prostate with strong FDG uptake on PET/CT.
Dong A; Zuo C; Lu J; Wang Y
Clin Nucl Med; 2014 Jul; 39(7):650-2. PubMed ID: 23877521
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer.
Shah RB; Zhou M; LeBlanc M; Snyder M; Rubin MA
Am J Surg Pathol; 2002 Sep; 26(9):1161-8. PubMed ID: 12218572
[TBL] [Abstract][Full Text] [Related]
28. Can basal cells be seen in adenocarcinoma of the prostate?: an immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody.
Oliai BR; Kahane H; Epstein JI
Am J Surg Pathol; 2002 Sep; 26(9):1151-60. PubMed ID: 12218571
[TBL] [Abstract][Full Text] [Related]
29. Rare expression of high-molecular-weight cytokeratin in adenocarcinoma of the prostate gland: a study of 100 cases of metastatic and locally advanced prostate cancer.
Yang XJ; Lecksell K; Gaudin P; Epstein JI
Am J Surg Pathol; 1999 Feb; 23(2):147-52. PubMed ID: 9989840
[TBL] [Abstract][Full Text] [Related]
30. The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level.
Minamimoto R; Uemura H; Sano F; Terao H; Nagashima Y; Yamanaka S; Shizukuishi K; Tateishi U; Kubota Y; Inoue T
Ann Nucl Med; 2011 Jan; 25(1):21-7. PubMed ID: 20931305
[TBL] [Abstract][Full Text] [Related]
31. Eosinophilic pneumonia and thoracic metastases as an initial manifestation of prostatic carcinoma.
Ishiguro T; Kimura H; Araya T; Minato H; Katayama N; Yasui M; Kasahara K; Fujimura M
Intern Med; 2008; 47(15):1419-23. PubMed ID: 18670149
[TBL] [Abstract][Full Text] [Related]
32. Basal Cell Carcinoma of Prostate With MSMB-NCOA4 Fusion and a Probable Basal Cell Carcinoma In Situ: Case Report.
Pedersen V; Petersen KS; Brasso K; Østrup O; Loya AC
Int J Surg Pathol; 2021 Dec; 29(8):850-855. PubMed ID: 33978524
[TBL] [Abstract][Full Text] [Related]
33. FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy.
Beauregard JM; Blouin AC; Fradet V; Caron A; Fradet Y; Lemay C; Lacombe L; Dujardin T; Tiguert R; Rimac G; Bouchard F; Pouliot F
Cancer Imaging; 2015 Mar; 15(1):2. PubMed ID: 25889163
[TBL] [Abstract][Full Text] [Related]
34. Asymptomatic Solitary Metastasis to the Testis From Prostate Carcinoma Detected by FDG PET/CT.
Hsieh TC; Lin CC; Kao CH; Wu YC; Sun SS
Clin Nucl Med; 2016 Jan; 41(1):86-7. PubMed ID: 26402135
[TBL] [Abstract][Full Text] [Related]
35. Low grade urothelial carcinoma mimicking basal cell hyperplasia and transitional metaplasia in needle prostate biopsy.
Arista-Nasr J; Martinez-Benitez B; Bornstein-Quevedo L; Aguilar-Ayala E; Aleman-Sanchez CN; Ortiz-Bautista R
Int Braz J Urol; 2016; 42(2):247-52. PubMed ID: 27256178
[TBL] [Abstract][Full Text] [Related]
36. PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer.
Jadvar H
J Nucl Med; 2016 Oct; 57(Suppl 3):25S-29S. PubMed ID: 27694167
[TBL] [Abstract][Full Text] [Related]
37. Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss of PTEN expression and overexpression of EGFR.
Simper NB; Jones CL; MacLennan GT; Montironi R; Williamson SR; Osunkoya AO; Wang M; Zhang S; Grignon DJ; Eble JN; Tran T; Wang L; Baldrige LA; Cheng L
Hum Pathol; 2015 Jun; 46(6):805-12. PubMed ID: 25870120
[TBL] [Abstract][Full Text] [Related]
38. Is further evaluation needed for incidental focal uptake in the prostate in 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography images?
Hwang I; Chong A; Jung SI; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K; Ryu SB
Ann Nucl Med; 2013 Feb; 27(2):140-5. PubMed ID: 23076866
[TBL] [Abstract][Full Text] [Related]
39. FDG-PET Versus PSMA-PET: A Patient With Prostate Cancer.
Kichloo A; Amir R; Aljadah M; Wani F; Solanki S; Singh J; Chugh SS
J Investig Med High Impact Case Rep; 2020; 8():2324709620941313. PubMed ID: 32646251
[TBL] [Abstract][Full Text] [Related]
40. FDG PET imaging in a patient with primary seminoma of the prostate.
Hayasaka K; Koyama M; Fukui I
Clin Nucl Med; 2011 Jul; 36(7):593-4. PubMed ID: 21637070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
